| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 84,246 | 168,109 | 109,306 | 133,368 |
| Cost of revenues | 2,359 | 18,815 | 24,737 | 21,505 |
| Cost of revenues - related party | 30,988 | 59,346 | 22,505 | 29,192 |
| Gross profit | 50,899 | 89,948 | 62,064 | 82,671 |
| General and administrative expenses | 311,379 | 1,245,360 | 1,542,444 | 523,855 |
| Salary and benefits | 542,420 | 628,343 | 626,598 | 242,941 |
| Advertising and marketing | 104,914 | 258,295 | 281,732 | 251,330 |
| Investor relations | 33,319 | 106,000 | 1,419,000 | 255,000 |
| Stock based compensation | 6,601,793 | 3,120,445 | 1,045,479 | 567,619 |
| Total operating expenses | 7,593,825 | 5,358,443 | 4,915,253 | 1,840,745 |
| Loss from operations | -7,542,926 | -5,268,495 | -4,853,189 | -1,758,074 |
| Interest expense | 75,850 | 21,700 | -13,700 | - |
| Interest expense amortization on discount | - | - | - | 241,620 |
| Loss from settlement | - | -125,625 | - | - |
| Total other (income) expense | -75,850 | -147,325 | 13,700 | -241,620 |
| Loss before income taxes | -7,618,776 | -5,415,820 | -4,839,489 | -1,999,694 |
| Net loss | -7,618,776 | -5,415,820 | -4,839,489 | -1,999,694 |
| Net loss attributed to non-controlling interest | -558 | -2 | -98 | -461 |
| Net loss attributed to mangoceuticals, inc | -7,618,218 | -5,415,818 | -4,839,391 | -1,999,233 |
| Preferred stock dividend requirements | 294,000 | - | - | - |
| Net loss attributed to mangoceuticals, inc. common stockholders | -7,912,218 | - | - | - |
| Basic | 11,524,275 | - | 4,593,063 | 2,013,848 |
| Basic loss per share | -0.69 | -0.57 | -1.29 | -0.99 |
| Diluted | 11,524,275 | 9,983,376 | 4,593,063 | 2,013,848 |
| Diluted loss per share | -0.69 | -0.57 | -1.29 | -0.99 |
MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC. (MGRX)